Keywords
How to Cite
Abstract
Until recently the detection of carriers of mutations in hereditary cancer genes was aimed almost exclusively to the detection of subjects-at-risk, and consequently, personalized monitoring and preventive actions. However, it was revealed several years ago that some hereditary cancers are characterized by unique biological features and, therefore, unusual spectrum of drug sensitivity. For example, BRCA1/2-associated cancers usually demonstrate somatic loss of the remaining gene allele, and, hence, tumor-specific defects of DNA repair of double-strand breaks. This mechanism determines increased sensitivity of BRCA1/2-related cancers to cisplatin, mitomycin C and PARP inhibitors. Cancers arising as a part of Lynch syndrome can be effectively treated by the modulators of immune response. Tumors in patients with tuberous sclerosis often regress after administration of mTOR inhibitors. For the time being, there is already about a dozen of drugs demonstrating specific activity towards certain categories of hereditary cancers.References
Alsop K., Fereday S., Meldrum C. et al. BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group // J Clin Oncol. - 2012. - Vol. 30. - P. 2654-2663.
Bronner C.E., Baker S.M., Morrison P.T. et al. Mutation in the DNA mismatch repair gene homologue hMLH1 is associated with hereditary non-polyposis colon cancer // Nature. - 1994. - Vol. 368. - P 258-261.
Byrski T., Dent R., Blecharz P. et al. Results of a phase II open-label, non-randomized trial of cisplatin chemotherapy in patients with BRCA1-positive metastatic breast cancer // Breast Cancer Res. - 2012. - Vol. -14. - R110.
Byrski T., Huzarski T., Dent R. et al. Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients // Breast Cancer Res Treat. - 2009. - Vol. 115 - P. 359-363.
Byrski T., Huzarski T., Dent R. et al. Pathologic complete response to neoadjuvant cisplatin in BRCA1-positive breast cancer patients // Breast Cancer Res Treat. - 2014. -Vol. 147. - P.401-405.
Coleman R.L., Sill M.W., Bell-McGuinn K. et al. A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation - An NRG Oncology/Gynecologic Oncology Group study // Gynecol Oncol. - 2015. - Vol. 137. - P. 386-391.
Farmer H., McCabe N., Lord C.J. et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy // Nature. - 2005. - Vol. 434. - P 917-921.
Fong P.C., Boss D.S., Yap T.A. et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers // N Engl J Med. - 2009. - Vol. 361. - P 123-134.
Gorodnova T.V., Sokolenko A.P., Ivantsov A.O. et al. High response rates to neoadjuvant platinum-based therapy in ovarian cancer patients carrying germ-line BRCA mutation // Cancer Lett. - 2015. - Vol. 369. - P 363-367.
Hennessy B.T., Timms K.M., Carey M.S. et al. Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer // J Clin Oncol. - 2010. - Vol. 28. - P. 3570-3576.
Hu C., Hart S.N., Bamlet W.R. et al. Prevalence of Pathogenic Mutations in Cancer Predisposition Genes among Pancreatic Cancer Patients // Cancer Epidemiol Biomarkers Prev. - 2016. - Vol. 25. - P 207-211.
Imyanitov E.N., Byrski T. Systemic treatment for hereditary cancers: a 2012 update // Hered Cancer Clin Pract. - 2013. - Vol. 11. - P. 2.
Imyanitov E.N., Moiseyenko V.M. Drug therapy for hereditary cancers // Hered Cancer Clin Pract. - 2011. - Vol. 9. - P. 5.
Knudson A.G. Two genetic hits (more or less) to cancer // Nat Rev Cancer. - 2001. - Vol. 2. - P. 157-162.
Krueger D.A., Care M.M., Holland K. et al. Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis // N Engl J Med. - 2010. - Vol. 363. - P. 1801-1811.
Le D.T., Uram J.N., Wang H. et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency // N Engl J Med. - 2015. - Vol. 372. - P. 2509-2520.
Ledermann J., Harter P., Gourley C. et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomized phase 2 trial // Lancet Oncol. - 2014. - Vol. 15. - P. 852-861.
Llosa N.J., Cruise M., Tam A. et al. The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints // Cancer Discov. - 2015. - Vol. 5. - P. 43-51.
Malkin D., Li F.P., Strong L.C. et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms // Science. - 1990. -Vol. 250. - P. 1233-1238.
Martins F.C., De S., Almendro V. et al. Evolutionary pathways in BRCA1-associated breast tumors // Cancer Discov. - 2012. - Vol. 6. - P. 503-511.
Mateo J., Carreira S., Sandhu S. et al. DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer // N Engl J Med. - 2015. - Vol. 373. - P. 1697-1708.
Miki Y., Swensen J., Shattuck-Eidens D. et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1 // Science. - 1994. - Vol. 266. - P. 66-71.
Moiseyenko V.M., Chubenko V.A., Moiseyenko F.V. et al. Evidence for clinical efficacy of mitomycin C in heavily pretreated ovarian cancer patients carrying germ-line BRCA1 mutation // Med Oncol. - 2014. - Vol. 10. - P. 199.
Moiseyenko V.M., Dolmatov G.D., Moiseyenko F.V. et al. High efficacy of cisplatin neoadjuvant therapy in a prospective series of patients carrying BRCA1 germ-line mutation // Med Oncol. - 2015. - Vol. 32. - P. 89.
Moiseyenko V.M., Protsenko S.A., Brezhnev N.V. et al. High sensitivity of BRCA1-associated tumors to cisplatin monotherapy: report of two cases // Cancer Genet Cytogenet. - 2010. - Vol. 197. - P. 91-94.
Moiseyenko V.M., Volkov N.M., Suspistin E.N. et al. Evidence for predictive role of BRCA1 and bTUBIII in gastric cancer // Med Oncol. - 2013. - Vol. 30. - P. 545.
O’Shaughnessy J., Schwartzberg L., Danso M.A. et al. Phase III study of iniparib plus gemcitabine and carboplatin versus gemcitabine and carboplatin in patients with metastatic triple-negative breast cancer // J Clin Oncol. - 2014. - Vol. 32. - P. 3840-3847.
Oza A.M., Cibula D., Benzaquen A.O. et al. Olaparib combined with chemotherapy for recurrent platinum sensitive ovarian cancer: a randomized phase 2 trial // Lancet Oncol. - 2015. - Vol. 16. - P. 87-97.
Plummer R., Lorigan P., Steven N. et al. A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation // Cancer Chemother Pharmacol. - 2013. - Vol. 71. - P. 1191-1199.
Sokolenko A.P., Mitiushkina N.V., Buslov K.G. et al. High frequency of BRCA1 5382insC mutation in Russian breast cancer patients // Eur J Cancer. - 2006. - Vol. 42. - P. 1380-1384.
Steinbach G., Lynch P.M., Phillips R.K. et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis // N Engl J Med. - 2000. - Vol. 342. - P. 1946-1952.
Tang J.Y., Mackay-Wiggan J.M., Aszterbaum M. et al. Inhibiting the hedgehog pathway in patients with the basal-cell nevus syndrome // N Engl J Med. - 2012. -Vol. 366. - P. 2180-2188.
Turner N.C., Tutt A.N. Platinum chemotherapy for BRCA1-related breast cancer: do we need more evidence? // Breast Cancer Res. - 2012. - Vol. 14. - P. 115.
Vilar E., Gruber S.B. Microsatellite instability in colorectal cancer-the stable evidence // Nat Rev Clin Oncol. - 2010. - Vol. 7. - P. 153-162.
Wells S.A. Jr., Gosnell J.E., Gagel R.F. et al. Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer // J Clin Oncol. - 2010. - Vol. 28. - P. 767-772.
All the Copyright statements for authors are present in the standart Publishing Agreement (Public Offer) to Publish an Article in an Academic Periodical 'Problems in oncology' ...